FDA grants priority review of Lilly’s Selpercatinib for NSCLC
Selpercatinib is an oral medicine under development for the treatment of cancers with abnormalities in the rearranged during…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Jan 20
Selpercatinib is an oral medicine under development for the treatment of cancers with abnormalities in the rearranged during…
29 Jan 20
Dupixent is used as a treatment for atopic dermatitis in children, aged between six and 11 years, whose…
The new type 2 diabetes treatment is a daily pill containing empagliflozin, linagliptin and extended release metformin hydrochloride
24 Jan 20
TAZVERIK is indicated for the treatment of metastatic epithelioid sarcoma in patients who are not eligible for complete…
21 Jan 20
Mayzent selectively binds to S1P1 and S1P5 receptors to prevent lymphocytes from leaving the lymph nodes and entering…
20 Jan 20
BBT-176 has demonstrated strong anti-tumour efficacy, and enhanced efficacy when used along with anti-EGFR antibodies in the pre-clinical…
17 Jan 20
The FDA approval is based on the results of SUSTAIN 6 cardiovascular outcomes trial (CVOT) which showed positive…
16 Jan 20
Dovato is a once-daily, single-pill, 2-drug regimen that combines integrase inhibitor (INI) dolutegravir, and the nucleoside reverse transcriptase…
16 Jan 20
Janssen has secured the European Commission approval of SPRAVATO nasal spray for treatment-resistant major depressive disorder (TRD), in…
13 Jan 20
Fostemsavir was submitted for the US FDA new drug application (NDA), and was granted FDA fast track and…